TABLE 2.
Exploration of subgroup differences based on unadjusted SVR12 frequencies
| Subpopulation | Counts | EBR/GZR* | Counts | LDV/SOF* | EBR/GZR vs. LDV/SOF |
|---|---|---|---|---|---|
| Percentage (CI) | Percentage (CI) | Difference (CI) | |||
| Overall | 556/586 | 94.9 (92.8–96.5)† | 349/359 | 97.2 (94.9–98.7) | −2.3 (−4.8 to 0.4) |
| With RBV | 40/46 | 87.0 (73.7–95.1) | 14/15 | 93.3 (68.1–99.8) | −6.4 (−20.1 to 17.8) |
| Without RBV | 516/540 | 95.6 (93.5–97.1) | 335/344 | 97.4 (95.1–98.8) | −1.8 (−4.2 to 0.9) |
| Black | 253/266 | 95.1 (91.8–97.4) | 153/159 | 96.2 (92.0–98.6) | −1.1 (−5.0 to 3.6) |
| Non-Black | 303/320 | 94.7 (91.6–96.9) | 196/200 | 98.0 (95.0–99.5) | −3.3 (−6.6 to 0.3) |
| Prior treatment | 56/62 | 90.3 (80.1–96.4) | 44/45 | 97.8 (88.2–99.9) | −7.5 (−17.5 to 3.2) |
| No prior treatment | 500/524 | 95.4 (93.3–97.0) | 305/314 | 97.1 (94.6–98.7) | −1.7 (−4.2 to 1.2) |
| Male | 312/329 | 94.8 (91.9–96.7) | 212/222 | 95.5 (91.9–97.5) | −0.7 (−4.3 to 3.4) |
| Female | 244/257 | 94.9 (91.5–97.0) | 137/137 | 100 (97.3–100) | −5.1 (−7.7 to −2.4) |
| Genotype 1a | 419/445 | 94.2 (91.6–96.0) | 254/260 | 97.7 (95.1–98.9) | −3.5 (−6.4 to −0.1) |
| Genotype 1b | 137/141 | 97.2 (92.9–98.9) | 95/99 | 96.0 (90.1–98.4) | 1.2 (−3.7 to 7.3) |
| Cirrhosis | 92/95 | 96.8 (91.0–99.3) | 63/67 | 94.0 (85.4–98.3) | 2.8 (−4.0 to 11.5) |
| No cirrhosis | 464/491 | 94.5 (92.1–96.3) | 286/292 | 97.9 (95.6–99.2) | −3.4 (−6.1 to −0.5) |
| NS5a RAS | 47/54 | 87.0 (75.1–94.6) | 42/47 | 89.4 (76.9–96.5) | −2.3 (−15.3 to 11.3) |
| No NS5a RAS | 485/506 | 95.8 (93.7–97.4) | 286/290 | 98.6 (96.5–99.6) | −2.8 (−5.0 to −0.2) |
*
As assigned by randomization.
†
95% CIs were computed using the Wilson score method.